Page 22 - TD-2-3

Tumor Discovery Targeted drug delivery systems for the treatment of tumors

Figure 6. Types of vesicular carriers extensively employed for antitumor therapy.

Table 8. Different types of vesicular carriers for tumor management
Vesicular Therapeutic agent Research highlights Study model Application References
system
Liposomes Mitoxantrone (MTO) (i) Minimum MTO toxicity MDAMB-231 breast Orthotopic breast [31]
(ii) Improved cellular uptake carcinoma model carcinoma
(iii) Suppressed and delayed tumor
growth
8
B16-ovalalbumin (i) Induced robust CD T lymphocytes B16-ovalbumin (B16-OVA) Melanoma and [135]
(B16-OVA), vaccine (ii) Impaired cell toxicity solid tumor melanoma immunotherapy
adjuvants (iii) Increased programmed cell death of mouse model
tumor cells
(iv) Significantly improved survival rate
anti-EGFR-9Arg- (i) Remarked siRNA transfection in lung LS174T-Luc cancer cells RNA interference [136]
lipoplexes cancer cells chemotherapy
(ii) Suppressed transcription of the
targeted gene
(iii) Efficiently inhibited tumor growth
Thermosensitive (i) Developed glutathione-sensitive HT-1080 murine model Fibrosarcoma and [137]
NGRpeptide-siRNA carrier (xenograft) cancer therapy
(ii) Predicted 86% encapsulation
efficiency and thermal stability
(iii) 3 times high in vivo performance of
cell-penetrating peptides embedded
in liposomes
Paclitaxel and (i) High cellular uptake by both active Non-small-cell lung cancer Lung cancer [138]
vinorelbine and passive targeting mode (NSCLC)-tumor-bearing
(ii) Lessened cell toxicity compared to C57BL/6 mice
free drug
(iii) Restricted lung metastasis

(Cont’d...)

Volume 2 Issue 3 (2023) 16 https://doi.org/10.36922/td.1356